Systematic Review: Cannabis for Gynecologic Pain Shows Promise but Lacks Standardization

Most women using cannabis for gynecologic pain reported relief in surveys, and clinical studies of PEA-combination medications showed significant pain reduction, but varying formulations prevent definitive conclusions.

Liang, Angela L et al.·Obstetrics and gynecology·2022·Moderate EvidenceSystematic Review
RTHC-04005Systematic ReviewModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Moderate Evidence
Sample
N=16

What This Study Found

Among 16 included studies, 13-27% of women used cannabis for gynecologic pain. Survey data showed 61-95.5% reported pain relief. Six prospective cohort studies and one RCT of PEA-combination medications reported significant pain relief, with an average decrease of 3.35 points on a 10-point scale after 3 months.

Key Numbers

5,189 articles screened; 16 met criteria; 13-27% cannabis use prevalence; 61-95.5% reported relief; 3.35-point average pain reduction on 10-point scale

How They Did This

Systematic review searching PubMed, EMBASE, Scopus, Cochrane, and ClinicalTrials.gov for studies of cannabinoids in nonpregnant adult women with gynecologic pain conditions (chronic pelvic pain, vulvodynia, endometriosis, interstitial cystitis, malignancy).

Why This Research Matters

Gynecologic pain conditions like endometriosis and chronic pelvic pain are common, often undertreated, and significantly impact quality of life. Cannabis-based treatments represent a potential alternative or complement to current options.

The Bigger Picture

The endocannabinoid system is concentrated in reproductive tissues, providing biological plausibility for cannabis-based treatments. But the field remains hampered by inconsistent formulations and dosing.

What This Study Doesn't Tell Us

Heterogeneous studies with varying cannabis formulations, delivery methods, and dosages. Most evidence comes from surveys rather than controlled trials.

Questions This Raises

  • ?Which specific formulations (THC vs CBD vs PEA) work best for which gynecologic conditions?
  • ?Would standardized dosing protocols produce more consistent results across studies?

Trust & Context

Key Stat:
3.35-point pain reduction on 10-point scale
Evidence Grade:
Systematic review of 16 studies, but most evidence comes from surveys and uncontrolled cohorts rather than RCTs.
Study Age:
Published in 2022
Original Title:
Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review.
Published In:
Obstetrics and gynecology, 139(2), 287-296 (2022)
Database ID:
RTHC-04005

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does cannabis help with endometriosis or pelvic pain?

Survey data from this review showed 61-95.5% of women reported pain relief, and clinical studies of PEA-combination medications found significant improvement. But varying formulations prevent definitive conclusions.

What cannabis doses were studied for gynecologic pain?

Studies used THC doses up to 70 mg and CBD doses up to 2,000 mg, with most women ingesting or inhaling cannabis multiple times per week.

Read More on RethinkTHC

Cite This Study

RTHC-04005·https://rethinkthc.com/research/RTHC-04005

APA

Liang, Angela L; Gingher, Erin L; Coleman, Jenell S. (2022). Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review.. Obstetrics and gynecology, 139(2), 287-296. https://doi.org/10.1097/AOG.0000000000004656

MLA

Liang, Angela L, et al. "Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review.." Obstetrics and gynecology, 2022. https://doi.org/10.1097/AOG.0000000000004656

RethinkTHC

RethinkTHC Research Database. "Medical Cannabis for Gynecologic Pain Conditions: A Systemat..." RTHC-04005. Retrieved from https://rethinkthc.com/research/liang-2022-medical-cannabis-for-gynecologic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.